Tao Jia-Yu, Zhu Jun, Gao Yu-Qiong, Jiang Min, Yin Hong
Department of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Transl Cancer Res. 2025 Feb 28;14(2):1479-1491. doi: 10.21037/tcr-2025-128. Epub 2025 Feb 26.
BACKGROUND AND OBJECTIVE: The conventional in vitro research on tumor mechanisms is typically based on two-dimensional (2D) culture of tumor cells, which has many limitations in replicating tumorigenesis processes. In contrast, the three-dimensional (3D) bioprinting has paved the way for the construction of more biomimetic in vitro tumor models. This article comprehensively elucidates the features of 3D bioprinting and meticulously summarizes its applications in several selected tumors, aiming to offer valuable insights for future relevant studies. METHODS: A literature search was conducted in the databases of PubMed and Web of Science for articles on 3D bioprinting for tumor model construction. KEY CONTENT AND FINDINGS: This article introduces various 3D bioprinting technologies for tumor model construction, focusing on their pros and cons, principles, and protocols. Several tumor models are presented, detailing their utility in tumorigenesis research and their constraints. To date, 3D bioprinting has been widely applied in oncology, addressing the limitation of traditional 2D tumor cell culture in replicating tumor microenvironment (TME). CONCLUSIONS: Advanced 3D bioprinting technology accurately replicates the complex TME and the heterogeneity of intratumor structures, enabling further tumor studies. It significantly fuels our understanding of tumor pathophysiology and offers new hope for cancer patients.
Transl Cancer Res. 2025-2-28
Bioprinting. 2021-6
Ann Transl Med. 2021-10
Int J Nanomedicine. 2023
Biofabrication. 2022-5-31
Front Bioeng Biotechnol. 2021-5-31
Biochem Biophys Res Commun. 2024-10-20
Mater Today Bio. 2025-2-4
Acta Biomater. 2019-2-15
World J Clin Oncol. 2025-7-24
Front Immunol. 2025-7-3
Nat Rev Cancer. 2024-8
Front Bioeng Biotechnol. 2024-5-24
CA Cancer J Clin. 2024
Int J Nanomedicine. 2023
Biochim Biophys Acta Rev Cancer. 2024-1
ACS Appl Bio Mater. 2024-1-15
Drug Deliv Transl Res. 2024-8